First-in-human Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults (clinicaltrials.gov) - May 22, 2025 - P1 | N=192 | Not yet recruiting | Sponsor: Clover Biopharmaceuticals AUS Pty
New P1 trial • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections
|